4//SEC Filing
Waltermire Robert E. 4
Accession 0000950170-24-075221
CIK 0001157601other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 9:39 PM ET
Size
8.6 KB
Accession
0000950170-24-075221
Insider Transaction Report
Form 4
Waltermire Robert E.
Senior VP, Chief Pharma Dev.
Transactions
- Exercise/Conversion
Common Stock
2024-06-14$87.09/sh+1,900$165,471→ 7,400 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-14−1,900→ 10,350 totalExercise: $87.09Exp: 2032-02-24→ Common Stock - Sale
Common Stock
2024-06-14$280.00/sh−1,900$532,000→ 5,500 total
Footnotes (1)
- [F1]All shares issued pursuant to the exercise of the options reported herein represent 1,900 shares underlying an overall option award of 12,250 shares. All exercised options had vested. As to the overall option for 12,250 shares, 25% of the shares underlying the option vested on February 24, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
Documents
Issuer
MADRIGAL PHARMACEUTICALS, INC.
CIK 0001157601
Entity typeother
Related Parties
1- filerCIK 0001876996
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 9:39 PM ET
- Size
- 8.6 KB